Viral infection in the development and progression of pediatric acute respiratory distress syndrome

Frontiers in Pediatrics

Volumn 4, Issue NOV, 2016, Pages

  Nye, Steven ^a   Whitley, Richard J ^a   Kong, Michele ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

ARDS; H1N1 subtype; Influenza A virus; Pediatrics; RSV; Viral infections

Indexed keywords

EID: 85031850954     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2016.00128     Document Type: Review

References (155)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet (1967) 2:319-23. doi: 10.1016/S0140-6736(67)90168-7
2. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med (1994) 149:818-24. doi:10.1164/ajrccm.149.3.7509706
3. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA (2012) 307:2526-33. doi:10.1001/jama.2012.5669
4. Thomas NJ, Jouvet P, Willson D. Acute lung injury in children-kids really aren't just "little adults". Pediatr Crit Care Med (2013) 14:429-32. doi:10.1097/PCC.0b013e31827456aa
5. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med (2015) 16:428-39. doi:10.1097/PCC.0000000000000350
6. Sweatt AJ, Levitt JE. Evolving epidemiology and definitions of the acute respiratory distress syndrome and early acute lung injury. Clin Chest Med (2014) 35:609-24. doi:10.1016/j.ccm.2014.08.002
7. Barreira ER, Munoz GO, Cavalheiro PO, Suzuki AS, Degaspare NV, Shieh HH, et al. Epidemiology and outcomes of acute respiratory distress syndrome in children according to the Berlin definition: a multicenter prospective study. Crit Care Med (2015) 43:947-53. doi:10.1097/CCM.0000000000000866
8. De Luca D, Piastra M, Chidini G, Tissieres P, Calderini E, Essouri S, et al. The use of the Berlin definition for acute respiratory distress syndrome during infancy and early childhood: multicenter evaluation and expert consensus. Intensive Care Med (2013) 39:2083-91. doi:10.1007/s00134-013-3110-x
9. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med (2000) 342:1301-8. doi:10.1056/NEJM200005043421801
10. Kallet RH, Jasmer RM, Pittet JF, Tang JF, Campbell AR, Dicker R, et al. Clinical implementation of the ARDS network protocol is associated with reduced hospital mortality compared with historical controls. Crit Care Med (2005) 33:925-9. doi:10.1097/01.CCM.0000162382.59289.9C
11. Erickson S, Schibler A, Numa A, Nuthall G, Yung M, Pascoe E, et al. Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicenter, observational study. Pediatr Crit Care Med (2007) 8:317-23. doi:10.1097/01.PCC.0000269408.64179.FF
12. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med (2009) 360:588-98. doi:10.1056/NEJMoa0804877
13. Jhung MA, Swerdlow D, Olsen SJ, Jernigan D, Biggerstaff M, Kamimoto L, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis (2011) 52(Suppl 1):S13-26. doi:10.1093/cid/ciq008
14. Dahlem P, van Aalderen WM, Hamaker ME, Dijkgraaf MG, Bos AP. Incidence and short-term outcome of acute lung injury in mechanically ventilated children. Eur Respir J (2003) 22:980-5. doi:10.1183/09031936.03.00003303
15. Lopez-Fernandez Y, Azagra AM, de la Oliva P, Modesto V, Sanchez JI, Parrilla J, et al. Pediatric acute lung injury epidemiology and natural history study: incidence and outcome of the acute respiratory distress syndrome in children. Crit Care Med (2012) 40:3238-45. doi:10.1097/CCM.0b013e318260caa3
16. Schene KM, van den Berg E, Wosten-van Asperen RM, van Rijn RR, Bos AP, van Woensel JB. FiO2 predicts outcome in infants with respiratory syncytial virus-induced acute respiratory distress syndrome. Pediatr Pulmonol (2014) 49:1138-44. doi:10.1002/ppul.22974
17. Blank R, Napolitano LM. Epidemiology of ARDS and ALI. Crit Care Clin (2011) 27:439-58. doi:10.1016/j.ccc.2011.05.005
18. Carr S. Seasonal and pandemic influenza: an overview with pediatric focus. Adv Pediatr (2012) 59:75-93. doi:10.1016/j.yapd.2012.04.016
19. Cox CM, Blanton L, Dhara R, Brammer L, Finelli L. 2009 Pandemic influenza A (H1N1) deaths among children-United States, 2009-2010. Clin Infect Dis (2011) 52(Suppl 1):S69-74. doi:10.1093/cid/ciq011
20. Rao S, Torok MR, Bagdure D, Cunningham MA, Williams JT, Curtis DJ, et al. A comparison of H1N1 influenza among pediatric inpatients in the pandemic and post pandemic era. J Clin Virol (2015) 71:44-50. doi:10.1016/j.jcv.2015.07.308
21. Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics (2013) 132:796-804. doi:10.1542/peds.2013-1493
22. Pariani E, Martinelli M, Canuti M, Jazaeri Farsani SM, Oude Munnink BB, Deijs M, et al. Influenza and other respiratory viruses involved in severe acute respiratory disease in northern Italy during the pandemic and postpandemic period (2009-2011). Biomed Res Int (2014) 2014:241298. doi:10.1155/2014/241298
23. Topfer L, Menk M, Weber-Carstens S, Spies C, Wernecke KD, Uhrig A, et al. Influenza A (H1N1) vs non-H1N1 ARDS: analysis of clinical course. J Crit Care (2014) 29:340-6. doi:10.1016/j.jcrc.2013.12.013
24. Kinikar AA, Kulkarni RK, Valvi CT, Mave V, Gupte N, Khadse S, et al. Predictors of mortality in hospitalized children with pandemic H1N1 influenza 2009 in Pune, India. Indian J Pediatr (2012) 79:459-66. doi:10.1007/s12098-011-0578-7
25. Farias JA, Fernandez A, Monteverde E, Vidal N, Arias P, Montes MJ, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med (2010) 36:1015-22. doi:10.1007/s00134-010-1853-1
26. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 351:472-7. doi:10.1016/S0140-6736(97)11212-0
27. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 353:1374-85. doi:10.1056/NEJMra052211
28. Kawachi S, Luong ST, Shigematsu M, Furuya H, Phung TT, Phan PH, et al. Risk parameters of fulminant acute respiratory distress syndrome and avian influenza (H5N1) infection in Vietnamese children. J Infect Dis (2009) 200:510-5. doi:10.1086/605034
29. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med (2008) 358:261-73. doi:10.1056/NEJMra0707279
30. Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Viral infections in the ICU. Curr Opin Crit Care (2008) 14:605-8. doi:10.1097/MCC.0b013e32830f1e12
31. Luyt CE, Combes A, Trouillet JL, Nieszkowska A, Chastre J. Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome. Presse Med (2011) 40:e561-8. doi:10.1016/j.lpm.2011.05.027
32. Wang M, Cai F, Wu X, Wu T, Su X, Shi Y. Incidence of viral infection detected by PCR and real-time PCR in childhood community-acquired pneumonia: a meta-analysis. Respirology (2015) 20:405-12. doi:10.1111/resp.12472
33. Sun B, He H, Wang Z, Qu J, Li X, Ban C, et al. Emergent severe acute respiratory distress syndrome caused by adenovirus type 55 in immunocompetent adults in 2013: a prospective observational study. Crit Care (2014) 18:456. doi:10.1186/s13054-014-0456-6
34. Hung KH, Lin LH. Adenovirus pneumonia complicated with acute respiratory distress syndrome: a case report. Medicine (2015) 94:e776. doi:10.1097/MD.0000000000000776
35. Hasvold J, Sjoding M, Pohl K, Cooke C, Hyzy RC. The role of human metapneumovirus in the critically ill adult patient. J Crit Care (2016) 31:233-7. doi:10.1016/j.jcrc.2015.09.035
36. Rao S, Messacar K, Torok MR, Rick AM, Holzberg J, Montano A, et al. Enterovirus D68 in critically ill children: a comparison with pandemic H1N1 influenza. Pediatr Crit Care Med (2016) 17(11):1023-31. doi:10.1097/PCC.0000000000000922
37. Carrigan DR. Adenovirus infections in immunocompromised patients. Am J Med (1997) 102:71-4. doi:10.1016/S0002-9343(97)00015-6
38. Hakim FA, Tleyjeh IM. Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature. Eur J Clin Microbiol Infect Dis (2008) 27:153-8. doi:10.1007/s10096-007-0416-z
39. World Health Organization. Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens. Workshop on Prioritization of Pathogens. (2015). Available from: http://www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en
40. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 348:1953-66. doi:10.1056/NEJMoa030781
41. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med (2003) 349:2431-41. doi:10.1056/NEJMra032498
42. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet (2003) 361:1767-72. doi:10.1016/S0140-6736(03)13412-5
43. Wang M, Yan M, Xu H, Liang W, Kan B, Zheng B, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis (2005) 11:1860-5. doi:10.3201/eid1112.041293
44. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol (2016) 14:523-34. doi:10.1038/nrmicro.2016.81
45. WHO Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr (2013) 5. doi:10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
46. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet (2015) 386:995-1007. doi:10.1016/S0140-6736(15)60454-8
47. Khalid I, Alraddadi BM, Dairi Y, Khalid TJ, Kadri M, Alshukairi AN, et al. Acute management and long-term survival among subjects with severe Middle East respiratory syndrome coronavirus pneumonia and ARDS. Respir Care (2016) 61:340-8. doi:10.4187/respcare.04325
48. Bruynseels P, Jorens PG, Demey HE, Goossens H, Pattyn SR, Elseviers MM, et al. Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet (2003) 362:1536-41. doi:10.1016/S0140-6736(03)14740-X
49. Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, Trouillet JL, et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med (2007) 175:935-42. doi:10.1164/rccm.200609-1322OC
50. Simoons-Smit AM, Kraan EM, Beishuizen A, Strack van Schijndel RJ, Vandenbroucke-Grauls CM. Herpes simplex virus type 1 and respiratory disease in critically-ill patients: real pathogen or innocent bystander? Clin Microbiol Infect (2006) 12:1050-9. doi:10.1111/j.1469-0691.2006.01475.x
51. Schuller D, Spessert C, Fraser VJ, Goodenberger DM. Herpes simplex virus from respiratory tract secretions: epidemiology, clinical characteristics, and outcome in immunocompromised and nonimmunocompromised hosts. Am J Med (1993) 94:29-33. doi:10.1016/0002-9343(93)90116-7
52. Hennus MP, van Montfrans JM, van Vught AJ, Tesselaar K, Boelens JJ, Jansen NJ. Life-threatening human herpes virus-6 infection in early childhood: presenting symptom of a primary immunodeficiency? Pediatr Crit Care Med (2009) 10:e16-8. doi:10.1097/PCC.0b013e31819bb956
53. Ryan DP, Doody DP. Treatment of acute pulmonary failure with extracorporeal support: 100% survival in a pediatric population. J Pediatr Surg (1992) 27:1111-6. doi:10.1016/0022-3468(92)90570-W
54. Huzly D, Kurz S, Ebner W, Dettenkofer M, Panning M. Characterisation of nosocomial and community-acquired influenza in a large university hospital during two consecutive influenza seasons. J Clin Virol (2015) 73:47-51. doi:10.1016/j.jcv.2015.10.016
55. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control (2007) 35:S65-164. doi:10.1016/j.ajic.2007.10.007
56. Dhar S, Marchaim D, Tansek R, Chopra T, Yousuf A, Bhargava A, et al. Contact precautions: more is not necessarily better. Infect Control Hosp Epidemiol (2014) 35:213-21. doi:10.1086/675294
57. Stockton J, Ellis JS, Saville M, Clewley JP, Zambon MC. Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol (1998) 36:2990-5
58. Boivin G, Cote S, Dery P, De Serres G, Bergeron MG. Multiplex real-time PCR assay for detection of influenza and human respiratory syncytial viruses. J Clin Microbiol (2004) 42:45-51. doi:10.1128/JCM.42.1.45-51.2004
59. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med (2009) 360:2605-15. doi:10.1056/NEJMoa0903810
60. Schutten M, van Baalen C, Zoeteweij P, Fraaij P. The influenza virus: disease, diagnostics, and treatment. MLO Med Lab Obs (2013) 45:38-40
61. Tuttle R, Weick A, Schwarz WS, Chen X, Obermeier P, Seeber L, et al. Evaluation of novel second-generation RSV and influenza rapid tests at the point of care. Diagn Microbiol Infect Dis (2015) 81:171-6. doi:10.1016/j.diagmicrobio.2014.11.013
62. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med (2012) 156:500-11. doi:10.7326/0003-4819-156-7-201204030-00403
63. Principi N, Esposito S. Antigen-based assays for the identification of influenza virus and respiratory syncytial virus: why and how to use them in pediatric practice. Clin Lab Med (2009) 29:649-60. doi:10.1016/j.cll.2009.07.006
64. Moesker FM, van Kampen JJ, Aron G, Schutten M, van de Vijver DA, Koopmans MP, et al. Diagnostic performance of influenza viruses and RSV rapid antigen detection tests in children in tertiary care. J Clin Virol (2016) 79:12-7. doi:10.1016/j.jcv.2016.03.022
65. World Health Organization. WHO Recommendations on the Use of Rapid Testing for Influenza Diagnosis. Geneva: WHO (2005)
66. Adams O, Weis J, Jasinska K, Vogel M, Tenenbaum T. Comparison of human metapneumovirus, respiratory syncytial virus and rhinovirus respiratory tract infections in young children admitted to hospital. J Med Virol (2015) 87:275-80. doi:10.1002/jmv.24025
67. Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J (2006) 25:680-6. doi:10.1097/01.inf.0000226912.88900.a3
68. Stranak Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS One (2016) 11:e0157446. doi:10.1371/journal.pone.0157446
69. Weisman L. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J (2003) 22:S33-7. doi:10.1097/01.inf.0000053883.08663.e5
70. Purcell K, Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J (2004) 23:418-23. doi:10.1097/01.inf.0000126273.27123.33
71. Yuksel B, Greenough A. Birth weight and hospital readmission of infants born prematurely. Arch Pediatr Adolesc Med (1994) 148:384-8. doi:10.1001/archpedi.1994.02170040050008
72. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med (2000) 154:55-61
73. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol (2002) 34:262-6. doi:10.1002/ppul.10169
74. Rodriguez DA, Rodriguez-Martinez CE, Cardenas AC, Quilaguy IE, Mayorga LY, Falla LM, et al. Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region. Pediatr Pulmonol (2014) 49:269-76. doi:10.1002/ppul.22781
75. Chen Y, Shang S, Tang Y, Zhang C, Tong M, Dai Y. Clinical features of severe influenza A (H1N1) virus infection. Indian J Pediatr (2013) 80:97-101. doi:10.1007/s12098-012-0784-y
76. Wright PF, Gruber WC, Peters M, Reed G, Zhu Y, Robinson F, et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis (2002) 185:1011-8. doi:10.1086/339822
77. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med (2003) 168:633-9. doi:10.1164/rccm.200210-1148OC
78. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis (2005) 191:1861-8. doi:10.1086/430008
79. Houben ML, Coenjaerts FE, Rossen JW, Belderbos ME, Hofland RW, Kimpen JL, et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol (2010) 82:1266-71. doi:10.1002/jmv.21771
80. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis (2011) 204:996-1002. doi:10.1093/infdis/jir494
81. Launes C, Garcia-Garcia JJ, Jordan I, Selva L, Rello J, Munoz-Almagro C. Viral load at diagnosis and influenza A H1N1 (2009) disease severity in children. Influenza Other Respir Viruses (2012) 6:e89-92. doi:10.1111/j.1750-2659.2012.00383.x
82. Li CC, Wang L, Eng HL, You HL, Chang LS, Tang KS, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis (2010) 16:1265-72. doi:10.3201/eid1608.091918
83. Redlberger-Fritz M, Hirk S, Buchinger D, Haberl R, Hell M, Perkmann-Nagele N, et al. Distinct differences in clinical manifestation and viral laboratory parameters between children and adults with influenza A(H1N1)pdm09 infection-a retrospective comparative analysis. J Med Virol (2014) 86:1048-55. doi:10.1002/jmv.23912
84. Hammer J, Numa A, Newth CJ. Acute respiratory distress syndrome caused by respiratory syncytial virus. Pediatr Pulmonol (1997) 23:176-83. doi:10.1002/(SICI)1099-0496(199703)23:3<176::AID-PPUL2>3.0.CO;2-M
85. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2008) 82:2040-55. doi:10.1128/JVI.01625-07
86. Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol (2013) 372:3-38. doi:10.1007/978-3-642-38919-1_1
87. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol (2007) 20:108-19. doi:10.1038/modpathol.3800725
88. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, et al. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A (2012) 109:5040-5. doi:10.1073/pnas.1110203109
89. van Schaik SM, Welliver RC, Kimpen JL. Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol (2000) 30:131-8. doi:10.1002/1099-0496(200008)30:2<131::AID-PPUL8>3.0.CO;2-S
90. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child (1996) 75:133-6. doi:10.1136/adc.75.2.133
91. Orwoll BE, Sapru A. Biomarkers in pediatric ARDS: future directions. Front Pediatr (2016) 4:55. doi:10.3389/fped.2016.00055
92. Kong MY, Gaggar A, Li Y, Winkler M, Blalock JE, Clancy JP. Matrix metalloproteinase activity in pediatric acute lung injury. Int J Med Sci (2009) 6:9-17. doi:10.7150/ijms.6.9
93. Kong MY, Whitley RJ, Peng N, Oster R, Schoeb TR, Sullender W, et al. Matrix metalloproteinase-9 mediates RSV infection in vitro and in vivo. Viruses (2015) 7:4230-53. doi:10.3390/v7082817
94. Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J (2013) 32:e437-42. doi:10.1097/INF.0b013e3182a14407
95. Fernandez JA, Tapia L, Palomino MA, Larranaga C, Pena M, Jaramillo H. Plasma interferon-gamma, interleukin-10 and soluble markers of immune activation in infants with primary adenovirus (ADV) and respiratory syncytial virus (RSV) infection. Eur Cytokine Netw (2005) 16:35-40
96. Vieira RA, Diniz EM, Ceccon ME. Correlation between inflammatory mediators in the nasopharyngeal secretion and in the serum of children with lower respiratory tract infection caused by respiratory syncytial virus and disease severity. J Bras Pneumol (2010) 36:59-66. doi:10.1590/S1806-37132010000100011
97. Aras S, Aiyar A, Amedee AM, Gallaher WR. Molecular character of influenza A/H1N1 2009: implications for spread and control. Indian J Microbiol (2009) 49:339-47. doi:10.1007/s12088-009-0060-7
98. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev (1992) 56:152-79
99. Manz B, Schwemmle M, Brunotte L. Adaptation of avian influenza A virus polymerase in mammals to overcome the host species barrier. J Virol (2013) 87:7200-9. doi:10.1128/JVI.00980-13
100. Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinary implications. J Mol Genet Med (2008) 3:158-66
101. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med (2002) 76:105-15. doi:10.1353/bhm.2002.0022
102. Gaydos JC, Top FH Jr, Hodder RA, Russell PK. Swine influenza a outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis (2006) 12:23-8. doi:10.3201/eid1201.050965
103. CDC. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep (2009) 58:400-2
104. Travanty E, Zhou B, Zhang H, Di YP, Alcorn JF, Wentworth DE, et al. Differential susceptibilities of human lung primary cells to H1N1 influenza viruses. J Virol (2015) 89:11935-44. doi:10.1128/JVI.01792-15
105. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol (2010) 177:166-75. doi:10.2353/ajpath.2010.100115
106. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med (2009) 361:680-9. doi:10.1056/NEJMoa0904252
107. Kido H. Influenza virus pathogenicity regulated by host cellular proteases, cytokines and metabolites, and its therapeutic options. Proc Jpn Acad Ser B Phys Biol Sci (2015) 91:351-68. doi:10.2183/pjab.91.351
108. Cheng XW, Lu J, Wu CL, Yi LN, Xie X, Shi XD, et al. Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm. Respir Physiol Neurobiol (2011) 175:185-7. doi:10.1016/j.resp.2010.11.004
109. Tiwari N, Kapoor P, Dhole TN. Antibody and inflammatory response-mediated severity of pandemic 2009 (pH1N1) influenza virus. J Med Virol (2014) 86:1034-40. doi:10.1002/jmv.23877
110. Takano T, Tajiri H, Kashiwagi Y, Kimura S, Kawashima H. Cytokine and chemokine response in children with the 2009 pandemic influenza A (H1N1) virus infection. Eur J Clin Microbiol Infect Dis (2011) 30:117-20. doi:10.1007/s10096-010-1041-9
111. Dessing MC, van der Sluijs KF, Florquin S, van der Poll T. Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. Clin Immunol (2007) 125:328-36. doi:10.1016/j.clim.2007.08.001
112. Hunt JL, Bronicki RA, Anas N. Role of inhaled nitric oxide in the management of severe acute respiratory distress syndrome. Front Pediatr (2016) 4:74. doi:10.3389/fped.2016.00074
113. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med (2006) 354:2564-75. doi:10.1056/NEJMoa062200
114. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med (2006) 354:1671-84. doi:10.1056/NEJMoa051693
115. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med (2013) 368:2159-68. doi:10.1056/NEJMoa1214103
116. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev (2011) 239:149-66. doi:10.1111/j.1600-065X.2010.00972.x
117. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J (2009) 28:655-8. doi:10.1097/INF.0b013e318199c3b1
118. Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol (2013) 372:259-84. doi:10.1007/978-3-642-38919-1_13
119. Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med (2015) 7:312ra175. doi:10.1126/scitranslmed.aac8463
120. Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, et al. Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate. J Virol (2015) 89:9499-510. doi:10.1128/JVI.01373-15
121. Geevarghese B, Simoes EA. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir Ther (2012) 17:201-11. doi:10.3851/IMP2061
122. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 176:1215-24. doi:10.1086/514115
123. Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: a real-world perspective. Int J Pediatr (2014) 2014:571609. doi:10.1155/2014/571609
124. Helmink BJ, Ragsdale CE, Peterson EJ, Merkel KG. Comparison of intravenous palivizumab and standard of care for treatment of respiratory syncytial virus infection in mechanically ventilated pediatric patients. J Pediatr Pharmacol Ther (2016) 21:146-54. doi:10.5863/1551-6776-21.2.146
125. Prais D, Danino D, Schonfeld T, Amir J. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest (2005) 128:2765-71. doi:10.1378/chest.128.4.2765
126. Lagos R, DeVincenzo JP, Munoz A, Hultquist M, Suzich J, Connor EM, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J (2009) 28:835-7. doi:10.1097/INF.0b013e3181a165e4
127. Ramilo O, Lagos R, Saez-Llorens X, Suzich J, Wang CK, Jensen KM, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J (2014) 33:703-9. doi:10.1097/INF.0000000000000240
128. Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther (2014) 3:133-58. doi:10.1007/s40121-014-0046-6
129. CDC. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep (2009) 58:521-4
130. Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One (2010) 5:e13755. doi:10.1371/journal.pone.0013755
131. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med (2009) 361:2414-23. doi:10.1056/NEJMoa0908535
132. Cuesta JG, Aavitsland P, Englund H, Gudlaugsson O, Hauge SH, Lyytikainen O, et al. Pandemic vaccination strategies and influenza severe outcomes during the influenza A(H1N1)pdm09 pandemic and the post-pandemic influenza season: the Nordic experience. Euro Surveill (2016) 21(16). doi:10.2807/1560-7917.ES.2016.21.16.30208
133. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med (1991) 325:24-9. doi:10.1056/NEJM199107043250105
134. Krilov LR. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J (2002) 21:479-81. doi:10.1097/00006454-200205000-00037
135. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science (1972) 177:705-6. doi:10.1126/science.177.4050.705
136. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev (2007) CD000181. doi:10.1002/14651858.CD000181.pub3
137. Luo YH, Huang CY, Yang KY, Lee YC. Inhaled ribavirin therapy in adult respiratory syncytial virus-induced acute respiratory distress syndrome. Arch Bronconeumol (2011) 47:315-7. doi:10.1016/j.arbres.2010.12.002
138. Kang SJ, Park KH, Kee SJ, Shin JH, Jung SI, Kwon YS, et al. Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection. Jpn J Infect Dis (2013) 66:425-7. doi:10.7883/yoken.66.425
139. American Academy of Pediatrics. Respiratory syncytial virus. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red Book®: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics (2015). p. 667-76
140. Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother (2005) 49:2460-6. doi:10.1128/AAC.49.6.2460-2466.2005
141. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 371:711-22. doi:10.1056/NEJMoa1401184
142. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 282:1240-6. doi:10.1001/jama.282.13.1240
143. Teke T, Coskun R, Sungur M, Guven M, Bekci TT, Maden E, et al. 2009 H1N1 influenza and experience in three critical care units. Int J Med Sci (2011) 8:270-7. doi:10.7150/ijms.8.270
144. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis (2011) 11:134. doi:10.1186/1471-2334-11-134
145. Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics (2011) 128:e1450-8. doi:10.1542/peds.2011-0774
146. Green TP, Moler FW, Goodman DM. Probability of survival after prolonged extracorporeal membrane oxygenation in pediatric patients with acute respiratory failure. Extracorporeal life support organization. Crit Care Med (1995) 23:1132-9. doi:10.1097/00003246-199506000-00021
147. Natt BS, Desai H, Singh N, Poongkunran C, Parthasarathy S, Bime C. Extracorporeal membrane oxygenation for ARDS: national trends in the United States 2008-2012. Respir Care (2016) 61:1293-8. doi:10.4187/respcare.04760
148. Dalton HJ, Macrae DJ. Extracorporeal support in children with pediatric acute respiratory distress syndrome: proceedings from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med (2015) 16:S111-7. doi:10.1097/PCC.0000000000000439
149. Khan JY, Kerr SJ, Tometzki A, Tyszczuk L, West J, Sosnowski A, et al. Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: a collaborative report. Arch Dis Child Fetal Neonatal Ed (1995) 73:F91-4. doi:10.1136/fn.73.2.F91
150. Steinhorn RH, Green TP. Use of extracorporeal membrane oxygenation in the treatment of respiratory syncytial virus bronchiolitis: the national experience, 1983 to 1988. J Pediatr (1990) 116:338-42. doi:10.1016/S0022-3476(05)80676-6
151. Flamant C, Hallalel F, Nolent P, Chevalier JY, Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr (2005) 164:93-8. doi:10.1007/s00431-004-1580-0
152. Streng A, Prifert C, Weissbrich B, Liese JG. Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11-2012/13. BMC Infect Dis (2015) 15:573. doi:10.1186/s12879-015-1293-1
153. Tokuhira N, Shime N, Inoue M, Kawasaki T, Sakurai Y, Kurosaka N, et al. Mechanically ventilated children with 2009 pandemic influenza A/H1N1: results from the National Pediatric Intensive Care Registry in Japan. Pediatr Crit Care Med (2012) 13:e294-8. doi:10.1097/PCC.0b013e31824fbb10
154. Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA (2009) 302:1888-95. doi:10.1001/jama.2009.1535
155. Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA (2011) 306:1659-68. doi:10.1001/jama.2011.1471